CN114026097A - 取代的吡唑并喹唑啉酮化合物及其应用 - Google Patents
取代的吡唑并喹唑啉酮化合物及其应用 Download PDFInfo
- Publication number
- CN114026097A CN114026097A CN202080046797.2A CN202080046797A CN114026097A CN 114026097 A CN114026097 A CN 114026097A CN 202080046797 A CN202080046797 A CN 202080046797A CN 114026097 A CN114026097 A CN 114026097A
- Authority
- CN
- China
- Prior art keywords
- alkyl
- substituted
- tetrahydro
- pyran
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
式I的化合物，或其立体异构体、互变异构体、N‑氧化物、水合物、同位素取代的衍生物、溶剂化物或其可药用盐，或其混合物，或其前药。式I的化合物是激酶抑制剂，可用于治疗因为DDR功能缺陷而引起的临床病症，例如癌症。
Description
PCT国内申请，说明书已公开。
Claims (11)
- PCT国内申请，权利要求书已公开。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910628148 | 2019-07-10 | ||
| CN2019106281482 | 2019-07-10 | ||
| PCT/CN2020/100869 WO2021004482A1 (zh) | 2019-07-10 | 2020-07-08 | 取代的吡唑并喹唑啉酮化合物及其应用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114026097A true CN114026097A (zh) | 2022-02-08 |
| CN114026097B CN114026097B (zh) | 2024-02-23 |
Family
ID=74114368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202080046797.2A Active CN114026097B (zh) | 2019-07-10 | 2020-07-08 | 取代的吡唑并喹唑啉酮化合物及其应用 |
Country Status (3)
| Country | Link |
|---|---|
| US (1) | US20220259211A1 (zh) |
| CN (1) | CN114026097B (zh) |
| WO (1) | WO2021004482A1 (zh) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117567485A (zh) * | 2023-11-27 | 2024-02-20 | 广州中医药大学(广州中医药研究院) | 一类含氟和三氟甲基季碳中心的吡喃衍生物及其制备方法和应用 |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| CN106255692A (zh) * | 2014-05-08 | 2016-12-21 | 阿斯利康(瑞典)有限公司 | 咪唑并[4,5‑c]喹啉‑2‑酮化合物以及它们在治疗癌症中的用途 |
| WO2018127195A1 (zh) * | 2017-01-09 | 2018-07-12 | 上海瑛派药业有限公司 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
-
2020
- 2020-07-08 CN CN202080046797.2A patent/CN114026097B/zh active Active
- 2020-07-08 WO PCT/CN2020/100869 patent/WO2021004482A1/zh not_active Ceased
- 2020-07-08 US US17/626,029 patent/US20220259211A1/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| CN106255692A (zh) * | 2014-05-08 | 2016-12-21 | 阿斯利康(瑞典)有限公司 | 咪唑并[4,5‑c]喹啉‑2‑酮化合物以及它们在治疗癌症中的用途 |
| WO2018127195A1 (zh) * | 2017-01-09 | 2018-07-12 | 上海瑛派药业有限公司 | 取代的稠合杂芳基化合物作为激酶抑制剂及其应用 |
| WO2018153365A1 (zh) * | 2017-02-27 | 2018-08-30 | 上海瑛派药业有限公司 | 取代的稠合杂芳三环化合物作为激酶抑制剂及其应用 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20220259211A1 (en) | 2022-08-18 |
| WO2021004482A1 (zh) | 2021-01-14 |
| CN114026097B (zh) | 2024-02-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2022199652A1 (en) | Five-membered heteroaryl-pyrimidine compounds as usp1 inhibitors and the use thereof | |
| KR102660196B1 (ko) | 치환된 축합 헤테로아릴기 화합물인 키나제 억제제 및 이의 응용 | |
| CN118215664B (zh) | 取代的三唑并杂芳基化合物作为usp1抑制剂及其应用 | |
| CN114728945B (zh) | 3,5-二取代吡唑化合物作为激酶抑制剂及其应用 | |
| CN110914277B (zh) | 咪唑并[1,2-b]嘧啶并[4,5-d]哒嗪-5(6H)-酮类化合物及其应用 | |
| EP4267581A1 (en) | Substituted imidazo[1,5-b]pyridazine compounds as kinase inhibitors and use thereof | |
| US11547703B2 (en) | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof | |
| CN114026097B (zh) | 取代的吡唑并喹唑啉酮化合物及其应用 | |
| WO2024083237A1 (en) | Substituted heteroaryl bicyclic compounds as usp1 inhibitors and the use thereof | |
| CN114787162B (zh) | 取代的咪唑并喹喔啉化合物及其应用 | |
| CN112480120A (zh) | 取代的咪唑并喹喔啉化合物及其应用 | |
| EP4673448A1 (en) | Substituted nitrogen-containing tricyclic compounds as parp inhibitors and the use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |